RE:RE:RE:Breast cancer treatment: perspectives on the oncolytic virusIn the event you missed it because you were caught up in your conspiracy "bot" stuff ... An exciting frontier remains the synergy between OVs and conventional treatments like chemotherapy, radiotherapy, and immunotherapy. Exploring combination therapies can capitalize on their complementary mechanisms, potentially amplifying therapeutic efficacy and overcoming resistance. It is also crucial to find strategies that restore the tumour microenvironment and bolster anti- tumour immune responses. This includes interventions that regulate immune checkpoints, modulate cytokine profiles, or stimulate adaptive immune cells within the tumour milieu. ONCY has demonstrated pelareorep's ability to 'prime' the innate and adaptive iimmune system and remodel an otherwise immunosuppressive tumor microenvironment (TME) in advance of the addition of an immune checkpoint inhibitor.
I was surprised to hear that Richard Vile of the Mayo Clinic only learned of the need to sequence in immune checkpoint inhibitors after the administration of an OV at the recent OV Conference in Banff. Perhaps his work in simultaneously adding pelareorep to CAR-T therapy and then using pelareorep to "boost" the immune system to recharge CAR-T cells to provide for a curative effect had something to do it.
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1375433/full